0000000000514588

AUTHOR

Romain Boidot

showing 20 related works from this author

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

2016

// Aurelie Bertaut 1 , Caroline Truntzer 2 , Rachid Madkouri 3 , Coureche Guillaume Kaderbhai 4 , Valentin Derangere 5 , Julie Vincent 4 , Bruno Chauffert 6 , Marie Helene Aubriot-Lorton 7 , Wahlid Farah 3 , Klaus Luc Mourier 3 , Romain Boidot 5,8 and Francois Ghiringhelli 4,5,8,9 1 Biostatistics unit Georges Francois Leclerc Cancer Center, Dijon, France 2 CLIPP, Research Center, University of Burgundy, Dijon, France 3 Department of Neurosurgery, CHU, Dijon, France 4 Department of Medical Oncology, Georges Francois Leclerc Cancer Center, Dijon, France 5 Platform of Transfer in Cancer Biology Genetic and histology, Georges Francois Leclerc Cancer Center, Dijon, France 6 Department of Medical…

0301 basic medicineOncologyMaleVascular Endothelial Growth Factor Agenetic structuresNeutrophilsmedicine.medical_treatmentAngiogenesis InhibitorsBiomarkers Pharmacological[ SDV.CAN ] Life Sciences [q-bio]/CancerLeukocyte Count0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactorEndothelial Growth-Factorprognostic factorNeoadjuvant therapyRandomized Controlled Trials as TopicNeovascularization PathologicBrain NeoplasmsColony-Stimulating FactorAge FactorsChemoradiotherapyMiddle AgedPrognosisNeoadjuvant Therapy3. Good healthTreatment OutcomeOncology030220 oncology & carcinogenesisTo-Lymphocyte RatioAbsolute neutrophil countFemalemedicine.drugmedicine.medical_specialtyBevacizumabMalignant Glioma[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologybevacizumabDisease-Free Survival03 medical and health sciencesInternal medicinemedicineHumansPretreatment NeutrophilKarnofsky Performance StatusSingle-Agent BevacizumabRetrospective StudiesNewly-Diagnosed GlioblastomaRecurrent Glioblastomabusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyGene Expression ProfilingglioblastomaCancerRetrospective cohort studyLomustinemedicine.diseasePhase-Ii Trialeye diseasesSurgeryIrinotecan030104 developmental biologyprognosistic factorBrain-Tumorssense organsClinical Research PaperNeoplasm Recurrence LocalbusinessChemoradiotherapyFollow-Up Studies
researchProduct

Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients

2016

International audience; Tumor-infiltrating T and B lymphocytes could have the potential to affect cancer prognosis. The objective of this study was to investigate the prognostic significance of tumor infiltration by CD8 and CD4 T cells, and B lymphocytes in patients with localized gastric cancer. In a retrospective cohort of 82 patients with localized gastric cancer and treated by surgery we quantitatively assessed by immunohistochemistry on surgical specimen, immune infiltrates of IL-17(+), CD8(+), Foxp3(+), Tbet(+) T cells and CD20(+) B cells both in the tumor core and at the invasive margin via immunohistochemical analyses of surgical specimens. We observed that CD8(+) and IL17(+) T-cell…

0301 basic medicinePathologymedicine.medical_specialtyStromal cellImmune contextureImmunologyB-cellsOvarian-cancer[SDV.CAN]Life Sciences [q-bio]/CancerExpressionFavorable prognosisT-bet[ SDV.CAN ] Life Sciences [q-bio]/Cancerhistology03 medical and health sciencesLong-term survival0302 clinical medicineImmune systemhuman tumorsmedicineImmunology and Allergy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyLymphocytesB cellOriginal ResearchCD20B cellsbiologybusiness.industrygastric cancerCarcinomaFOXP3medicine.disease3. Good health030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisbiology.protein[SDV.IMM]Life Sciences [q-bio]/ImmunologyprognosisbusinessOvarian cancerTertiary lymphoid structuresInfiltration (medical)Lung-cancerCD8
researchProduct

Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.

2021

Primary triple-negative invasive lobular breast carcinomas (TN-ILCs), which do not express hormone receptors and HER2 at diagnosis, are rare and poorly known. In this study, we analyzed the largest TN-ILC series ever reported in the literature, in comparison to phenotypically similar breast tumor subtypes: triple-negative invasive ductal carcinoma (TN-IDC) and hormone receptor-positive invasive lobular carcinoma (HR + ILC). All primary TN-ILCs registered in our database between 2000 and 2018 (n = 38) were compared to tumors from control groups, matched by stage and Elston/Ellis grade, with regard to clinical, pathologic, and immunohistochemical characteristics. A comparative molecular analy…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPathologyReceptor ErbB-2Lobular carcinomaDNA Mutational AnalysisTriple Negative Breast NeoplasmsArticlePathology and Forensic Medicine03 medical and health sciencesBasal (phylogenetics)Phosphatidylinositol 3-Kinases0302 clinical medicineBreast cancerInternal medicinemedicineCarcinomaHumansskin and connective tissue diseasesSurvival analysisAgedAged 80 and overbusiness.industryMiddle Agedmedicine.diseaseAndrogen receptorbody regionsCarcinoma Lobular030104 developmental biologyPleomorphism (cytology)Receptors EstrogenReceptors Androgen030220 oncology & carcinogenesisInvasive lobular carcinomaMutationFemalebusinessModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
researchProduct

The receptor NLRP3 is a transcriptional regulator of TH2 differentiation.

2015

The receptor NLRP3 is involved in the formation of the NLRP3 inflammasome that activates caspase-1 and mediates the release of interleukin 1β (IL-1β) and IL-18. Whether NLRP3 can shape immunological function independently of inflammasomes is unclear. We found that NLRP3 expression in CD4(+) T cells specifically supported a T helper type 2 (TH2) transcriptional program in a cell-intrinsic manner. NLRP3, but not the inflammasome adaptor ASC or caspase-1, positively regulated a TH2 program. In TH2 cells, NLRP3 bound the Il4 promoter and transactivated it in conjunction with the transcription factor IRF4. Nlrp3-deficient TH2 cells supported melanoma tumor growth in an IL-4-dependent manner and …

CD4-Positive T-LymphocytesInflammasomesImmunologyBlotting WesternBiologyInterleukin 21MiceTh2 CellsCell Line TumorNLR Family Pyrin Domain-Containing 3 ProteinImmunology and AllergyCytotoxic T cellAnimalsIL-2 receptorPromoter Regions GeneticInterleukin 3Oligonucleotide Array Sequence AnalysisMice KnockoutCD40integumentary systemReverse Transcriptase Polymerase Chain ReactionZAP70Gene Expression ProfilingCell DifferentiationNeoplasms ExperimentalAsthmaCell biologyGene Expression Regulation NeoplasticMice Inbred C57BLInterleukin 10Interferon Regulatory FactorsInterleukin 12biology.proteinNIH 3T3 CellsTrans-ActivatorsFemaleInterleukin-4Carrier ProteinsProtein BindingSignal TransductionNature immunology
researchProduct

Human ectonucleotidase-expressing CD25 high Th17 cells accumulate in breast cancer tumors and exert immunosuppressive functions

2015

IF 7.644; International audience; Th17 cells contribute to the development of some autoimmune and allergic diseases by driving tissue inflammation. However, the function of Th17 cells during cancer progression remains controversial. Here, we show that human memory CD25(high) Th17 cells suppress T cell immunity in breast cancer. Ectonucleotidase-expressing Th17 cells accumulated in breast cancer tumors and suppressed CD4(+) and CD8(+) T cell activation. These cells expressed both Ror gamma t and Foxp3 genes and secreted Th17 related cytokines. We further found that CD39 ectonucleotisase expression on tumor-infiltrating Th17 cells was driven by TGF-beta and IL-6. Finally, immunohistochemical …

0301 basic medicineAdenosineT cellImmunologyGeneration[SDV.CAN]Life Sciences [q-bio]/Cancerchemical and pharmacologic phenomenaBiology[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciencesInterleukin 21Immune systembreast cancerCancer stem cellmedicineCd73Immunology and AllergyChemotherapy[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyIL-2 receptorRegulatory T-CellsSuppressionCarcinomaFOXP3hemic and immune systemsSuicide gene3. Good healthReceptor Ccr6030104 developmental biologymedicine.anatomical_structurePhenotypeOncologyImmunologyInterleukin 12[SDV.IMM]Life Sciences [q-bio]/ImmunologyTh17prognosisectonucleotidase
researchProduct

Accumulation of MDSC and Th17 Cells in Patients with Metastatic Colorectal Cancer Predicts the Efficacy of a FOLFOX-Bevacizumab Drug Treatment Regimen

2016

Abstract Host immunity controls the development of colorectal cancer, and chemotherapy used to treat colorectal cancer is likely to recruit the host immune system at some level. Athough preclinical studies have argued that colorectal cancer drugs, such as 5-fluorouracil (5-FU) and oxaliplatin, exert such effects, their combination as employed in the oncology clinic has not been evaluated. Here, we report the results of prospective immunomonitoring of 25 metastatic colorectal cancer (mCRC) patients treated with a first-line combination regimen of 5-FU, oxaliplatin, and bevacizumab (FOLFOX–bevacizumab), as compared with 20 healthy volunteers. Before this therapy was initiated, T regulatory ce…

0301 basic medicineOncologyCancer ResearchOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentLeucovorinKaplan-Meier EstimatePolymerase Chain ReactionSuppressor-Cells[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineFOLFOXAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesProgressionFlow Cytometry3. Good healthBevacizumabOncology030220 oncology & carcinogenesisFluorouracilColorectal Neoplasmsmedicine.drugmedicine.medical_specialtyBevacizumabT-Cells[SDV.CAN]Life Sciences [q-bio]/CancerDisease-Free Survival03 medical and health sciencesInternal medicinemedicineCarcinomaHumansChemotherapyTumorsInflammationChemotherapyAntitumor Immunitybusiness.industryMyeloid-Derived Suppressor CellsCarcinomaCancermedicine.diseasedigestive system diseasesOxaliplatinRegimen030104 developmental biologyTherapiesImmunologyTh17 CellsPoor-Prognosisbusiness
researchProduct

Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?

2020

Abstract Introduction Non-small-cell lung cancer (NSCLC) is one of the most common and deadly cancers. Several molecular drivers of oncogene addiction are now known to be strong predictive biomarkers for target therapies. Advances in large Next Generation Sequencing (LNGS) have improved the ability to detect potentially targetable mutations. However, the integration of LNGS into clinical management in an individualized manner remains challenging. Methods In this single-center observational study we included all patients with advanced NSCLC who underwent LNGS. Somatic and germline exome analysis was performed with a restriction on 323 cancer related genes. Variants were classified and Molecu…

Pulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentGermlineTargeted therapyInternal medicineCarcinoma Non-Small-Cell LungMedicineHumansExomeLung cancerExomeLungbusiness.industryHigh-Throughput Nucleotide SequencingOncogenesPrecision medicinemedicine.diseaseCancer related genesmedicine.anatomical_structureOncologyMutationNon small cellbusinessLung cancer (Amsterdam, Netherlands)
researchProduct

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?

2016

IF 5.008; International audience; Anti-EGFR therapy and antiangiogenic therapies are used alone or in combination with chemotherapies to improve survival in metastatic colorectal cancer. However, it is unknown whether pretreatment with antiangiogenic therapy could impact on the efficacy of anti-EGFR therapy. We selected one hundred and twenty eight patients diagnosed with advanced colorectal cancer with a KRAS and NRAS unmutated tumor. These patients were treated with cetuximab or panitumumab alone or with chemotherapy as second or third-line. Univariate and multivariate Cox model analysis were performed to estimate the effect of a previous bevacizumab regimen on progression free survival a…

0301 basic medicineNeuroblastoma RAS viral oncogene homologOncologyMaleVascular Endothelial Growth Factor AColorectal cancerCetuximabAngiogenesis Inhibitorsmedicine.disease_causeTrialGTP PhosphohydrolasesRas mutations[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsDrug InteractionsAged 80 and overCetuximabPanitumumabAntibodies MonoclonalMiddle Aged3. Good healthErbB ReceptorsOncology030220 oncology & carcinogenesisFemaleKRASColorectal Neoplasms1st-Line treatmentmedicine.drugResearch PaperAdultSTAT3 Transcription Factormedicine.medical_specialtyBevacizumabAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.BC]Life Sciences [q-bio]/Cellular BiologybevacizumabIrinotecanDisease-Free SurvivalTumor angiogenesisProto-Oncogene Proteins p21(ras)03 medical and health sciencesVEGFRInternal medicineCell Line TumormedicinePanitumumabHumansEndothelial growth-FactorChemotherapyProgression-free survivalAgedbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyMembrane Proteinsmetastatic colon cancerStat-3medicine.diseaseVascular Endothelial Growth Factor Receptor-2IrinotecanRandomized phase-III030104 developmental biologyanti-EGFR therapyFactor receptorCaco-2 Cellsbusiness
researchProduct

A Short Caspase-3 Isoform Inhibits Chemotherapy-Induced Apoptosis by Blocking Apoptosome Assembly

2011

Alternative splicing of caspase-3 produces a short isoform caspase-3s that antagonizes caspase-3 apoptotic activity. However, the mechanism of apoptosis inhibition by caspase-3s remains unknown. Here we show that exogenous caspase-3 sensitizes MCF-7 and HBL100 breast cancers cells to chemotherapeutic treatments such as etoposide and methotrexate whereas co-transfection with caspase-3s strongly inhibits etoposide and methotrexate-induced apoptosis underlying thus the anti-apoptotic role of caspase-3s. In caspase-3 transfected cells, lamin-A and α-fodrin were cleaved when caspase-3 was activated by etoposide or methotrexate. When caspase-3s was co-transfected, this cleavage was strongly reduc…

Models MolecularImmunoprecipitationScienceBlotting WesternMolecular Sequence DataGene ExpressionApoptosisBreast NeoplasmsCaspase 3BiologyReal-Time Polymerase Chain ReactionBiochemistryRNA interferenceApoptosomesCell Line TumorMolecular Cell BiologyBreast CancermedicineHumansAmino Acid SequenceBiologyEtoposideDNA PrimersMultidisciplinaryCell DeathBase SequenceSequence Homology Amino AcidCaspase 3QRObstetrics and GynecologyTransfectionApoptosome assemblyMolecular biologyEnzymesEnzyme ActivationIsoenzymesApoptosisCancer researchMedicineApoptosomeResearch Articlemedicine.drugPLoS ONE
researchProduct

Liver X Receptor ligand cytotoxicity in colon cancer cells and not in normal colon epithelial cells depends on LXRβ subcellular localization

2015

Increasing evidence indicates that Liver X Receptors (LXRs) have some anticancer properties. We recently demonstrated that LXR ligands induce colon cancer cell pyroptosis through an LXRβ-dependent pathway. In the present study, we showed that human colon cancer cell lines presented differential cytoplasmic localizations of LXRβ. This localization correlated with caspase-1 activation and cell death induction under treatment with LXR ligand. The association of LXRβ with the truncated form of RXRα (t-RXRα) was responsible for the sequestration of LXRβ in the cytoplasm in colon cancer cells. Moreover t-RXRα was not expressed in normal colon epithelial cells. These cells presented a predominantl…

LXRβCytoplasmmedicine.medical_specialtyHydrocarbons FluorinatedColonColorectal cancerCaspase 1BiologyLigandsCell Line03 medical and health sciences0302 clinical medicineCell Line TumorInternal medicineRXRαsubcellular localizationmedicineHumansIntestinal MucosaLiver X receptorCytotoxicityLiver X Receptors030304 developmental biologySulfonamides0303 health sciencesRetinoid X Receptor alphaRetinoid X receptor alphaCaspase 1PyroptosisEpithelial CellsHCT116 CellsOrphan Nuclear ReceptorsSubcellular localizationmedicine.disease3. Good healthEnzyme ActivationGene Expression Regulation NeoplasticEndocrinologycolon cancerOncologyCell culture030220 oncology & carcinogenesisColonic NeoplasmsCancer researchPriority Research PaperOncotarget
researchProduct

Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage

2020

International audience; Intestinal microbiota have been proposed to induce commensal-specific memory T cells that cross-react with tumor-associated antigens. We identified major histocompatibility complex (MHC) class I-binding epitopes in the tail length tape measure protein (TMP) of a prophage found in the genome of the bacteriophage Enterococcus hirae Mice bearing E. hirae harboring this prophage mounted a TMP-specific H-2Kb-restricted CD8+ T lymphocyte response upon immunotherapy with cyclophosphamide or anti-PD-1 antibodies. Administration of bacterial strains engineered to express the TMP epitope improved immunotherapy in mice. In renal and lung cancer patients, the presence of the ent…

H-2 AntigenProgrammed Cell Death 1 ReceptorCD8-Positive T-LymphocytesEpitopeEpitopesFecesMice0302 clinical medicineEnterococcus hiraeNeoplasmsMonoclonalBacteriophages0303 health sciencesMultidisciplinarybiologyAntibodies MonoclonalViral Tail ProteinsAlkylating3. Good healthmedicine.anatomical_structure030220 oncology & carcinogenesisCross ReactionEpitopeImmunotherapyHumanT cellAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/CancerCross ReactionsMajor histocompatibility complexAntibodiesMicrobiology03 medical and health sciencesAnimals; Antibodies Monoclonal; Antigens Neoplasm; Antineoplastic Agents Alkylating; Bacteriophages; CD8-Positive T-Lymphocytes; Cross Reactions; Cyclophosphamide; Enterococcus hirae; Epitopes; Feces; Gastrointestinal Microbiome; H-2 Antigens; Histocompatibility Antigens Class I; Humans; Immunotherapy; Mice; Neoplasms; Programmed Cell Death 1 Receptor; Viral Tail Proteins[SDV.CAN] Life Sciences [q-bio]/CancerAntigenAntigens NeoplasmMHC class ImedicineAnimalsHumansAntigensBacteriophageAntineoplastic Agents AlkylatingCyclophosphamideProphage030304 developmental biologyEnterococcus hiraeAnimalHistocompatibility Antigens Class IH-2 AntigensCD8-Positive T-Lymphocytebiology.organism_classificationGastrointestinal Microbiomebiology.proteinNeoplasmFeceCD8
researchProduct

The role of telomeres in predicting individual radiosensitivity of patients with cancer in the era of personalized radiotherapy.

2014

Radiotherapy plays a key role in cancer treatments, but tumor cell death differs from one tumor to another. The response of patients to radiotherapy varies considerably and adverse side effects are difficult to prevent. The mechanisms involved in the heterogeneity of this response are not well understood. In order to enhance the efficacy and safety of radiotherapy, it is important to identify subpopulations most at risk of developing a late adverse response to radiotherapy. Telomeres are composed of multiple repeats of a unique sequence of nucleotides forming a TTAGGG pattern. They protect chromosomes from end-to-end fusion and maintain genomic stability. Telomeres have been shown to be ext…

GeneticsTelomerasebusiness.industrymedicine.medical_treatmentCancerGeneral MedicineTelomeremedicine.diseaseRadiation ToleranceTelomereRadiation therapyTelomerase RNA componentOncologyMRN complexPredictive Value of TestsChromosome instabilityNeoplasmsmedicineCancer researchAnimalsHumansRadiology Nuclear Medicine and imagingTelomerase reverse transcriptasePrecision MedicinebusinessCancer treatment reviews
researchProduct

Effects of tumor mutation burden on the antigen presentation pathway

2021

AbstractTumor mutation burden (TMB) is used to select patients to receive immune checkpoint inhibitors (ICIs) but has mixed predictive capabilities. We hypothesized that inactivation of antigen presenting genes (APGs) that result from increased TMBs would result in inherent resistance to ICIs. We observed that somatic mutations in APGs were associated with increasing TMBs across 9,418 tumor samples of 33 different histological subtypes. In adenocarcinomas of the lung, ITGAX and CD1B were some of the most commonly mutated APGs. In 62 patients with non-small cell lung cancers treated with a PD-1 inhibitor in second or later lines of therapy, there was an association of increased TMB with muta…

MutationLungbusiness.industrySomatic cellCellmedicine.disease_causemedicine.anatomical_structureAntigenmedicineCancer researchNivolumabAllelebusinessGene
researchProduct

The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells

2014

The TH9 subset of helper T cells was initially shown to contribute to the induction of autoimmune and allergic diseases, but subsequent evidence has suggested that these cells also exert antitumor activities. However, the molecular events that account for their effector properties are elusive. Here we found that the transcription factor IRF1 enhanced the effector function of TH9 cells and dictated their anticancer properties. Under TH9-skewing conditions, interleukin 1β (IL-1β) induced phosphorylation of the transcription factor STAT1 and subsequent expression of IRF1, which bound to the promoters of Il9 and Il21 and enhanced secretion of the cytokines IL-9 and IL-21 from TH9 cells. Further…

OvalbuminGreen Fluorescent ProteinsImmunologyMelanoma ExperimentalProto-Oncogene Proteins c-fyn3T3 cellsCell LineInterferon-gammaMicemedicineAnimalsImmunology and AllergySTAT1PhosphorylationRNA Small InterferingSTAT4Transcription factorInterleukin 3Mice KnockoutBase SequencebiologySequence Analysis RNAChemistryEffectorInterleukinsInterleukin-9Promoter3T3 CellsT-Lymphocytes Helper-InducerInterleukin-10Cell biologyMice Inbred C57BLSTAT1 Transcription Factormedicine.anatomical_structureCell culturebiology.proteinFemaleRNA InterferenceInterferon Regulatory Factor-1Nature Immunology
researchProduct

TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer.

2021

Simple Summary High-grade serous ovarian carcinoma (HGSC) could be analyzed with a molecular stratification defined by different genomic instability signatures associated with specific mutational process and prognostic biomarkers. Immune infiltrate is known to be a robust biomarker in HGSC. We aimed to investigate immune parameters according to genomic instability signatures. We observed that homologous recombination deficiency positive, copy cumber variant signature 7 and TCR (T cells receptor) clonality are good prognostic biomarkers in HGSC. Combining TCR clonality and genomic instability signature or T cell infiltration improved the prognostic value compared to each variable taken alone…

Genome instabilityCancer ResearchTumor microenvironmentmedicine.medical_treatmentT cellT-cell receptorTCR clonalityNeoplasms. Tumors. Oncology. Including cancer and carcinogensbiomarkersImmunotherapyBiologyHGSCArticleSerous fluidImmune systemmedicine.anatomical_structureOncologyHRDmedicineCancer researchCopy-number variationprognosticRC254-282Cancers
researchProduct

Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients

2019

Abstract Purpose: Immune checkpoint inhibitors revolutionized the treatment of non-small cell lung cancer (NSCLC). However, only one-quarter of patients benefit from these new therapies. PD-L1 assessment and tumor mutational burden (TMB) are available tools to optimize use of checkpoint inhibitors but novel tools are needed. Exome sequencing could generate many variables but their role in identifying predictors of response is unknown. Experimental Design: We performed somatic and constitutional exome analyses for 77 patients with NSCLC treated with nivolumab. We studied: one-tumor-related characteristics: aneuploidy, CNA clonality, mutational signatures, TMB, mutations in WNT, AKT, MAPK, an…

Male0301 basic medicineCancer ResearchLung NeoplasmsDNA repairAntineoplastic AgentsPembrolizumabAntibodies Monoclonal HumanizedB7-H1 AntigenDisease-Free Survival03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineCarcinoma Non-Small-Cell LungExome SequencingBiomarkers TumorHumansMedicineCTLA-4 AntigenLung cancerExomeExome sequencingAgedRetrospective StudiesAged 80 and overbusiness.industryGenomicsMiddle Agedmedicine.diseaseIpilimumabNivolumabTreatment Outcome030104 developmental biologyOncology030220 oncology & carcinogenesisMutationMonoclonalCancer researchBiomarker (medicine)FemaleNivolumabbusinessClinical Cancer Research
researchProduct

An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibi…

2021

Simple Summary PARP inhibitors, a family of targeted cancer therapeutics, have been shown to be efficient in patients with some deficiencies in the homologous recombination machinery. However, a quick and reliable identification of patients who would benefit from such therapies remains a challenge. In particular, patients with tumors carrying variants of unknown significance (VUS) in homologous recombination genes do not currently benefit from PARP inhibitor treatments. In this study, we present an algorithm that may allow classification of these variants with regard to their impact on tumor responsiveness to PARP inhibitors. If validated on a larger patient sample, our algorithm would allo…

0301 basic medicineCancer ResearchIn silicohomologous recombinationArticleOlaparib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHomologous chromosomeMedicineProgression-free survivalAllele frequencyPARP inhibitorsSensitizationRC254-282responsePerformance statusbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensVUS030104 developmental biologymedicine.anatomical_structureOncologychemistry030220 oncology & carcinogenesisPARP inhibitorbusinessAlgorithmprogression-free survivalCancers
researchProduct

Detection of KRAS, NRAS and BRAF somatic mutations in circulating tumor DNA using two assays of Next Generation Sequencing (NGS) for patients with me…

2015

National audience

[ SDV.BBM.GTP ] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN][SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN][SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]ComputingMilieux_MISCELLANEOUS
researchProduct

Transcriptome-wide identification of transient RNA G-quadruplexes in human cells

2018

Guanine-rich RNA sequences can fold into four-stranded structures, termed G-quadruplexes (G4-RNAs), whose biological roles are poorly understood, and in vivo existence is debated. To profile biologically relevant G4-RNA in the human transcriptome, we report here on G4RP-seq, which combines G4-RNA-specific precipitation (G4RP) with sequencing. This protocol comprises a chemical crosslinking step, followed by affinity capture with the G4-specific small-molecule ligand/probe BioTASQ, and target identification by sequencing, allowing for capturing global snapshots of transiently folded G4-RNAs. We detect widespread G4-RNA targets within the transcriptome, indicative of transient G4 formation in…

Cell ExtractsNoncoding RnasScienceGene-Expression[SDV.CAN]Life Sciences [q-bio]/CancerWeb ServerLigandsModels BiologicalArticleExpression AnalysisTranslation Regulation Expression Analysis Gene-Expression Noncoding Rnas Dna Structures Small-Molecule Human Genome Web Server Real-Time ChromatinHumansImmunoprecipitation[CHIM]Chemical Sciences[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyDna Structureslcsh:Science[SDV.GEN]Life Sciences [q-bio]/GeneticsTranslation RegulationQHuman GenomeReal-TimeChromatinG-QuadruplexesMCF-7 CellsRNARNA Long Noncodinglcsh:QTranscriptomeSmall-Molecule
researchProduct

Solid papillary carcinoma with reverse polarity of the breast displays morphologic, immunohistochemical and molecular characteristics in comparison t…

2018

IF 6.655 (2017); International audience

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologySolid papillary carcinoma[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyCancer
researchProduct